ADAP Market Cap History
Below is a table of the ADAP market cap history going back to 10/18/2017:

Date ADAP Market Cap
10/18/2017608.37M

Also see: ADAP Shares Outstanding History
and ADAP YTD Return
Mouse over chart for data details
10/18/2017
Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing cell therapies to patients, particularly in solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables Co. to identify cancer targets, find and genetically engineer T-cell receptors, and produce therapeutic candidates for administration to patients. Co. has three SPEAR T-cells in clinical trials, ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4) and ADP-A2AFP (AFP). A fourth SPEAR T-cell, the NY-ESO SPEAR T-cell is Co.'s collaboration with GlaxoSmithKline. We show 1 historical shares outstanding datapoints in our ADAP shares outstanding history coverage, used to compute ADAP market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ADAP market cap history over the course of time is important for investors interested in comparing ADAP's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ADAP versus a peer is one thing; comparing ADAP market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ADAP can fluctuate over the course of history. With this page we aim to empower investors researching ADAP by allowing them to research the ADAP market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ADAP:
ADAP SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adaptimmune Therapeutics (ADAP) is categorized under the Miscellaneous sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

ADIL Market Cap History
ADNT Market Cap History
ADYX Market Cap History
AESE Market Cap History
AEYE Market Cap History
AFIN Market Cap History
AFMD Market Cap History
AFYA Market Cap History
AGBA Market Cap History
AGMH Market Cap History
More Miscellaneous companies »

 

ADAP Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.